Brief: Celularity And Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement To Distribute Biovance And Biovance 3L Ocular For Ophthalmic Applications
27/07/2023 15:04
July 27 (Reuters) - Celularity Inc CELU.O :
* CELULARITY AND VERSÉA OPHTHALMICS ANNOUNCE EXCLUSIVE U.S.
COMMERCIALIZATION AGREEMENT TO DISTRIBUTE BIOVANCE® AND
BIOVANCE® 3L OCULAR FOR OPHTHALMIC APPLICATIONS
* CELULARITY INC - TERMS OF AGREEMENT ARE NOT DISCLOSED
Source text for Eikon: ID:nGNX3MDrwW
Further company coverage: CELU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celularity
See all newsU.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Celularity hits over 4-month high on deal to manufacture MuseCell's cell therapy platform
Celularity rises on deal to manufacture MuseCell's cell therapy platform
Brief: Celularity And MuseCell Innovations® Announce U.S. Manufacturing Collaboration For The Dezawa Musecell® Platform